AMRN Amarin Corp

RNS Number:3182K
Amarin Corporation Plc
11 October 2006




     AMARIN ANNOUNCES GRANT OF PATENT IN THE UNITED STATES FOR MIRAXION IN
                              HUNTINGTON'S DISEASE

LONDON, United Kingdom, October 11, 2006 Amarin Corporation plc (NASDAQ: AMRN)
today announces that the United States Patent and Trademark Office has granted
approval for its patent application covering the use of its proprietary
ultra-pure ethyl-EPA compound ("Miraxion") in Huntington's disease. The patent,
number 7,119,118, will run to 2021.

Rick Stewart, Chief Executive Officer commented, "We believe this patent
substantially enhances Miraxion's already significant commercial potential.
Amarin has additional patents granted for Miraxion in other central nervous
system disorders, such as depression, and has many patents pending for a range
of indications. We are committed to further strengthening our existing
intellectual property portfolio to protect the future market for Miraxion."

About Amarin
Amarin is a neuroscience company focused on the research, development and
commercialisation of novel drugs for the treatment of central nervous system
disorders.  Amarin has a late-stage drug development pipeline.  Miraxion,
Amarin's lead development compound, is in Phase III development for Huntington's
disease, Phase II development for depressive disorders and preclinical
development for Parkinson's disease.  Amarin's core development pipeline also
includes the recently acquired global rights to a novel oral formulation of
apomorphine for treating patients with advanced Parkinson's disease.

Miraxion for Huntington's disease is being developed under a Special Protocol
Assessment agreed with the US Food and Drug Administration ("FDA"), has been
granted Fast Track designation by the FDA and has received Orphan Drug
designation in the US and Europe.

Amarin maintains its primary stock market listing in the US on NASDAQ ("AMRN")
and secondary listings in the UK and Ireland on AIM ("AMRN") and IEX ("H2E")
respectively.

For press releases and other corporate information, visit the Amarin website at
http://www.amarincorp.com. Information on our website does not form part of this
press release.

Contacts:
Amarin                                               +44 (0) 207 907 2442
Rick Stewart                                         Chief Executive Officer
Alan Cooke                                           Chief Financial Officer
investor.relations@amarincorp.com

Investors:
Lippert/Heilshorn & Associates, Inc.                 +1 212 838 3777
Kim Golodetz
Anne Marie Fields

Media:
Powerscourt                                          +44 (0) 207 236 5615
Rory Godson
Victoria Brough

Disclosure Notice:

The information contained in this document is as of October 11, 2006. Amarin
assumes no obligation to update any forward-looking statements contained in this
document as a result of new information or future events or developments. This
document contains forward-looking statements about Amarin's financial condition,
results of operations, business prospects and products in research that involve
substantial risks and uncertainties. You can identify these statements by the
fact that they use words such as "will", "anticipate", "estimate", "project",
"forecast", "intend", "plan", "believe" and other words and terms of similar
meaning in connection with any discussion of future operating or financial
performance or events. Among the factors that could cause actual results to
differ materially from those described or projected herein are the following:
the success of Amarin's research and development activities, including the phase
III trials with Miraxion in Huntington's; decisions by regulatory authorities
regarding whether and when to approve Amarin's drug applications, as well as
their decisions regarding labelling and other matters that could affect the
commercial potential of Amarin's products; the speed with which regulatory
authorizations, pricing approvals and product launches may be achieved; the
success with which developed products may be commercialized; competitive
developments affecting Amarin's products under development; the effect of
possible domestic and foreign legislation or regulatory action affecting, among
other things, pharmaceutical pricing and reimbursement, including under Medicaid
and Medicare in the United States, and involuntary approval of prescription
medicines for over-the-counter use; Amarin's ability to protect its patents and
other intellectual property; claims and concerns that may arise regarding the
safety or efficacy of Amarin's product candidates; governmental laws and
regulations affecting Amarin's operations, including those affecting taxation;
Amarin's ability to maintain sufficient cash and other liquid resources to meet
its operating requirements; general changes in U.K. and US generally accepted
accounting principles; growth in costs and expenses; and the impact of
acquisitions, divestitures and other unusual items, including Amarin's ability
to integrate its acquisition of Amarin Neuroscience Limited. A further list and
description of these risks, uncertainties and other matters can be found in
Amarin's Annual Report on Form 20-F for the fiscal year ended December 31, 2005,
and in its Reports of Foreign Issuer on Form 6-K furnished to the SEC.

Ends.




                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
MSCFFUFLFSMSELS

Amarin (LSE:AMRN)
Historical Stock Chart
From Jan 2025 to Feb 2025

Amarin (LSE:AMRN)
Historical Stock Chart
From Feb 2024 to Feb 2025